Back to results
US 12,326,492 B2Granted
Systems and methods of detecting interstitial cystitis
AssigneeLipella Pharmaceuticals Inc.
InventorsJonathan Kaufman, Michael B. Chancellor
Life of this patent
Estimating the term…
Abstract
The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.
Claims40
A method for measuring permeability of a body cavity in a patient comprising:
- administering a composition comprising a T1-reducing contrast agent and a T2-reducing contrast agent directly into or onto the body cavity of the patient;
- imaging the body cavity in the patient, the body cavity comprising a lumen and a luminal surface, the lumen having the T1-reducing contrast agent and the T2-reducing contrast agent;
- and
- determining diffusion of the T1-reducing contrast agent from the lumen of the body cavity across the luminal surface of the body cavity,
- wherein diffusion of the T1-reducing contrast agent across the luminal surface of the body cavity is indicative of permeability of the body cavity associated with pathologic breakdown of one or more layers of the body cavity,
- wherein the T2-reducing contrast agent is retained within the lumen, and
- wherein the body cavity is urinary bladder or ureters.
4 more elements
A method for measuring permeability of a body cavity in a patient comprising:
- imaging the body cavity in the patient after administering a composition comprising a T1-reducing contrast agent and a T2-reducing contrast agent directly into or onto the body cavity of the patient, the body cavity comprising a lumen and a luminal surface, the lumen having the T1-reducing contrast agent and the T2-reducing contrast agent;
- and
- determining diffusion of the T1-reducing contrast agent from the lumen of the body cavity across the luminal surface of the body cavity,
- wherein diffusion of the T1-reducing contrast agent across the luminal surface of the body cavity is indicative of permeability of the body cavity associated with pathologic breakdown of one or more layers of the body cavity,
- wherein the T2-reducing contrast agent is retained within the lumen, and
- wherein the body cavity in the patient is urinary bladder or ureters.
3 more elements
Dependencies are inferred from the claim text.